Table 1. Main patient characteristics at primary treatment.
| Indices | Conservative surgery Total number (%) |
IBTR following conservative surgery Total number (%) |
Mastectomy Total number (%) |
|---|---|---|---|
| Total number | 3,293 | 338 | 844 |
| Age (year) | |||
| ≤40 | 600 (18.2) | 102 (30.2) | 147 (17.4) |
| 41-50 | 1,258 (38.2) | 136 (40.2) | 345 (40.9) |
| 51-60 | 855 (26.0) | 69 (20.4) | 234 (27.7) |
| >60 | 580 (17.6) | 31 (9.2) | 118 (14.0) |
| Menopausal status | |||
| Pre | 1,905 (57.9) | 244 (72.2) | 523 (62.0) |
| Post | 1,375 (41.8) | 92 (27.2) | 321(38.0) |
| N.A. | 13 (0.3) | 2 (0.6) | - |
| Tumor size | |||
| ≤2 cm | 2,794 (84.8) | 286 (84.6) | 546 (64.7) |
| >2 cm | 400 (12.1) | 41 (12.1) | 298 (35.3) |
| N.A. | 99 (3.1) | 11 (3.3) | - |
| Nodal status | |||
| N- | 2,079 (63.1) | 237 (70.1) | 263 (31.2) |
| N+ (1-3) | 883 (26.8) | 82 (24.3) | 342 (40.5) |
| N+ (>3) | 331 (10.1) | 19 (5.6) | 239 (28.3) |
| Systemic adjuvant therapy (for N+ patients) | |||
| None | 115 (9.5) | 15 (15.0) | 29 (5.0) |
| CMF ± Dx | 884 (72.8) | 71 (70.0) | 552 (95.0) |
| Tamoxifen | 153 (12.6) | 11 (11.0) | - |
| N.A. | 62 (5.1) | 4 (4.0) | - |
N.A., not available; CMF, cyclophosphamide + methotrexate + fluorouracil; Dx, doxorubicin